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Abstract
Background: According to the scientific literature, less than 30 borderline ovarian tumors have been karyotyped
and less than 100 analyzed for genomic imbalances by CGH.
Methods: We report a series of borderline ovarian tumors (n = 23) analyzed by G-banding and karyotyping as well
as high resolution CGH; in addition, the tumors were analyzed for microsatellite stability status and by FISH for
possible 6q deletion.
Results: All informative tumors were microsatellite stable and none had a deletion in 6q27. All cases with an
abnormal karyotype had simple chromosomal aberrations with +7 and +12 as the most common. In three tumors
with single structural rearrangements, a common breakpoint in 3q13 was detected. The major copy number
changes detected in the borderline tumors were gains from chromosome arms 2q, 6q, 8q, 9p, and 13q and losses
from 1p, 12q, 14q, 15q, 16p, 17p, 17q, 19p, 19q, and 22q. The series included five pairs of bilateral tumors and, in
two of these pairs, informative data were obtained as to their clonal relationship. In both pairs, similarities were
found between the tumors from the right and left side, strongly indicating that bilaterality had occurred via a
metastatic process. The bilateral tumors as a group showed more aberrations than did the unilateral ones,
consistent with the view that bilaterality is a sign of more advanced disease.
Conclusion: Because some of the imbalances found in borderline ovarian tumors seem to be similar to imbalances
already known from the more extensively studied overt ovarian carcinomas, we speculate that the subset of
borderline tumors with detectable imbalances or karyotypic aberrations may contain a smaller subset of tumors
with a tendency to develop a more malignant phenotype. The group of borderline tumors with no imbalances
would, in this line of thinking, have less or no propensity for clonal evolution and development to full-blown
carcinomas.
Introduction
Borderline ovarian tumors are of low malignant poten-
tial. They exhibit more atypical epithelial proliferation
than is seen in adenomas, their benign counterpart, but
are without the destructive stromal invasion characteris-
tic of overt adenocarcinomas [1]. Although the clinical
and pathological features of tumors of borderline malig-
nancy thus are intermediate, it is not clear whether they
represent a transitional form between adenomas and
invasive carcinomas, as a stage in multistep carcinogen-
esis, or alternatively, whether all three tumor types
should be regarded as independent entities brought
about by different molecular mechanisms [1,2].
Although a comparison of the cytogenetic abnormal-
ities occurring in ovarian carcinomas and tumors of
borderline malignancy could provide insights into their
pathogenetic relationship, little information is available
on the karyotypic patterns of the latter tumors. Indeed,
whereas chromosomal abnormalities have been reported
in over 400 ovarian carcinomas [3], the corresponding
cytogenetic information on borderline tumors is limited
to only 27 cases [4-11]. Karyotypic simplicity with few
or no structural rearrangements seems to be characteris-
tic with trisomies for chromosomes 7 and 12 as the
most common abnormalities [6-9]. Using fluorescent in
situ hybridization (FISH), Tibiletti et al. [2] found
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any medium, provided the original work is properly cited.consistent loss of a small area of 6q in a high percentage
of borderline ovarian tumors.
Several studies have used comparative genomic hybri-
dization (CGH) to identify the imbalances present in
tumor genomes, also in the ovarian context. Of nearly
100 borderline tumors analyzed, half have shown geno-
mic imbalances. The most frequent abnormalities thus
detected have been gains of or from chromosomes 5, 8,
and 12 and losses from 1p [12-17].
We here report a series (n = 23) of borderline ovarian
tumors analyzed by G-banding, high resolution (HR)-
CGH, FISH-examination for possible 6q deletions and
3q rearrangements, and a microsatellite instability (MSI)
assay. The latter analysis was included because ovarian
cancer can be part of the hereditary non-polyposis colon
cancer (HNPCC) spectrum which is often characterized
by MSI.
Materials and methods
Tumors
The examined material consisted of 23 fresh samples
from ovarian tumors surgically removed at The Norwe-
gian Radium Hospital from 2001 to 2004 (Table 1). The
tumors were all classified as borderline, either with ser-
ous (17 cases, Fig. 1), mucinous (5 cases), or a mixed
serous and mucinous differentiation (case 18). In five
patients, bilateral borderline tumors were analyzed
(cases 7 and 8, 9 and 10, 13 and 14, 19 and 20, and 22
and 23; hence, the total number of patients was 18).
The utilization of the tumor material for research pur-
poses was approved by institutional as well as regional
ethical committees.
Cell Culturing and Karyotyping
The tumor samples were manually minced and disaggre-
gated with Collagen II (Worthington, Freehold, NJ,
USA) until a suitable suspension of cells and cell clumps
was obtained. After 6-7 days of culturing in a selective
medium [18], colchicine was added and the cultures
harvested according to Mandahl [19]. The chromosomes
of the dividing cells were then G-banded and a karyo-
type established according to the recommendations of
the ISCN [20].
Fluorescence in Situ Hybridization (FISH) Analyses
BAC clones retrieved from the RPCI-11 Human BAC
library and the CalTech human BAC library (P. de Jong
libraries, http://bacpac.chori.org/home.htm) were used.
The clones were selected according to their physical and
genetic mapping data on chromosomes 3 and 6 as
reported by the Human Genome Browser at the Univer-
sity of California, Santa Cruz website http://genome.
ucsc.edu/. The clones specific for chromosome 3 were
selected because they mapped to around the 3q13
breakpoint seen in three of the tumors we examined
(see below and Table 2). The clones mapping on chro-
mosome 6 spanned the region between markers D6S193
and D6S149, i.e., the consistent deletion reported by
Tibiletti et al. [2] in the chromosomal region 167, 113,
548-167, 765, 926 in band 6q27 (Table 2). All clones
were grown in selective media and DNA was extracted
according to standard methods [21], DNA probes were
directly labelled with a combination of fluorescein iso-
thiocyanate (FITC)-12-deoxicytidine triphosphate
(dCTP) and FITC-12-2-deoxyuridine triphosphate
(dUTP), Texas Red-6-dCTP and Texas Red-dUTP (New
England Nuclear, Boston, MA, USA), and Cy3-dCTP
(GE Healthcare, UK) by nick translation. The subse-
quent hybridization conditions as well as the detection
procedure were according to standard protocols [22].
T h eh y b r i d i z a t i o n sw e r ea n a l y z e du s i n gaC y t o V i s i o n
system (Applied Imaging, Newcastle, UK).
High-Resolution Comparative Genomic Hybridization (HR-
CGH)
DNA was isolated by the phenol-chloroform method as
previously described [23]. CGH was performed accord-
ing to our modifications of standard procedures
[24,25]. Chromosomes were karyotyped based on their
inverted DAPI appearance and the relative hybridiza-
tion signal intensity was determined along each chro-
mosome. On average, 10-15 metaphases were analyzed.
A negative (normal versus normal; the normal control
was a pool of DNAs from four healthy women) and a
positive (the colon cancer cell line LOVO with known
copy number changes) control were included in the
experiments. For the scoring of CGH results, we
adopted the use of dynamic standard reference inter-
vals (D-SRI). A D-SRI represents a “normal” ratio pro-
file that takes into account the amount of variation
detected in negative controls for each chromosome
band. This provides a more objective and sensitive
scoring criterion than fixed thresholds [26-28] and,
consequently, a higher resolution. The D-SRI used was
generated with data from 10 normal versus normal
hybridizations (totalling 110 cells). This interval was
automatically scaled onto each sample profile, and
aberrations were scored whenever the case profile and
the standard reference profile at 99% confidence inter-
vals did not overlap. The description of the CGH copy
number changes was based on the recommendation of
the ISCN [20].
Microsatellite Instability Status
Microsatellite instability (MSI) status was determined in
all samples using a consensus panel of five microsatellite
markers (BAT25, BAT26, D2S123, D5S346, and
D17S250) [29]. A tumor was considered to be MSI-high
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Analysis.
Case num/
lab num
Type Surface Extraovarian Karyotype Genomic imbalances MS
status
1/01-642 mucinous no no 47, XX, +12[4]/47, XX, +7
[3]/45, XX, -6[3]/46, XX[63]
rev ish enh(1q22q32, 2p25, 2q22q24, 2q32q33, 3p12p14,
3p22, 3p23, 3p24, 3q12q13, 3q24, 3q25, 5p14, 5q14q22,
6q12q21, 6q22q23, 8q13, 8q21, 8q22q24, 9p13p21, 9p23,
10q21, 18q12), dim(1p21, 1p31pter, 7q11, 11p15,
11q12q14, 11q23, 12q23, 12q24, 13q12, 13q14, 13q33q34,
14q21q24, 14q31q32, 15q13q14, 15q22q24, 17p11p13,
17q, 19p13, 19q, 22q11q13)
MSS
2/01-700 mucinous no no 46, XX[116] rev ish enh(8q23, 9p23), dim(1p34p35, 7q11, 17p12p13,
19p13, 19q13, 22q11q12)
MSS
3/01-839 serous yes non-invasive
implants
46, XX, t(3;17) (q13;q24)[2]/
46, XX[45]
rev ish enh(3p13, 9p23p24), dim(1p33pter, 7q11, 9q34,
11q13, 12q24, 16p11p13, 17p12pter, 17q12q21, 19p13,
19q, 22q11q13)
no DNA
available
4/01-844 mucinous no no 46, XX, +12, -22[7]/46, XX
[19]
no DNA available MSS
5/02-1 serous yes no 46, XX[16]/92, XXXX[23] rev ish enh(2q22q24, 2q31q32, 3p12, 3q12q13, 4p15,
4q13, 5p14, 5q14q23, 6q15q16, 8q22, 8q23, 13q21q31,
13q32, 21q21), dim(1p32pter, 2q37, 3p21, 4q35, 5q35,
6p21, 6p22, 6q25, 7q11, 9q22, 9q33qter, 10q26,
11q12q13, 12p11p12, 12p13, 12q23q24, 14q31,
15q22q24, 16p11p13, 16q22q23, 17p11p13, 17q11q21,
17q22q24, 19p13, 19q13, 20q11q13, 21q22, 22q11q13)
MSS
6/02-329 serous yes invasive
implants
46, XX[28] no imbalances no DNA
available
7/02-828 A Serous
(right
ovary)
yes no 46, XX[13]/92, XXXX[7] rev ish enh(4p15, 8q22q23, 13q22q31, 13q32), dim
(1p32p36, 7p12p13, 7q11, 9q34, 11q12q13, 12p11p12,
12q23, 12q24, 15q22q24, 16p13, 17p12pter, 17q11q21,
19, 22q11q13)
MSS
8/02-829 B serous
(left ovary)
yes no 46, XX[106]/92, XXXX[9] no DNA available –
9/03-325 A serous
(right
ovary)
yes no 46, XX[15] rev ish enh(3p12p14, 3q13, 5p14, 6q15q16, 8q22q23,
9p21, 18q12), dim(1p31pter, 2q37, 7q11, 11q12q13,
12q24, 16p11p13, 17p11p13, 17q11q21, 17q23q25, 19p,
19q13, 22q11q13)
MSS
10/03-328 B serous
(left ovary)
yes no 46, XX[15] no imbalances MSS
11/03-401 serous no no Culture failure rev ish enh(1p32pter, 1q21q22, 2p11p12, 2q37, 3p21,
4p16, 6p12p21, 9q33qter, 10q22q23, 10q24, 10q25,
10q26, 11q11q14, 12q24, 14q32, 15q22q25, 16p,
16q13qter, 17p, 17q11q22, 17q24qter, 19p13, 19q13,
20p11p12, 20q13, 22q11q13), dim(6q15q21, 6q22q24)
MSS
12/03-481 serous yes no 46, XX[32] no imbalances MSS
13/03-620 A serous
(right
ovary)
yes metastasis
lympho
node
46, XX, der(4) t(3;4) (q13;
q34)[15]/46, XX[2]
no imbalances MSS
14/03-621 B serous
(left ovary)
yes metastasis
lympho
node
46, XX, der(4) t(3;4) (q13;
q34)[10]/46, XX[5]
no imbalances MSS
15/03-701 serous no no 46, XX[11] no imbalances MSS
16/04-36 serous yes invasive
implants
49, XX, +3, +7, i(8)(q10),
+12 [15]/50, idem, +r[2]/
50, idem, -r, +mar[2]
rev ish enh(3, 7, 8q13qter, 12), dim(8p22pter) MSS
17/04-682 mucinous no no 46, XX[3] no DNA available –
18/04-721 mucinous
and
serous
no no 46, XX[18] no imbalances MSS
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compared to normal DNA, MSI-low if only one marker
deviated from the normal pattern, and microsatellite
stable (MSS) if none of the tumor genotypes showed an
aberrant pattern. Control DNA corresponding to the
individual tumors was not available from the patients
and therefore single allele changes, i.e., the presence of
two different alleles, can reflect a heterozygous constitu-
tional genotype or a homozygous genotype with a novel
tumor-specific allele. Thus, dinucleotide markers were
not scored when such a pattern appeared in the tumors.
The MSI status was assessed according to Wu et al.
[30]. Allelic sizes were determined using GeneMapper
3.7 software (Applied Biosystems, Foster City, CA, USA)
and the results were independently scored by two inves-
tigators. A second round of analyses was always per-
formed and confirmed the findings.
Results
The cell culturing and subsequent G-banding cytoge-
netic analysis gave informative results in 21 samples
(Table 1), seven of which showed an abnormal karyo-
type whereas 14 were normal. The remaining two sam-
ples were culture failures and therefore could not be
examined using this technique. All the cases with an
abnormal karyotype had simple chromosomal aberra-
tions. In three tumors, a single structural rearrangement
was seen in a pseudodiploid karyotype: a t(3;17)(q13;
q24) was detected in case 3 and a der(4)t(3;4)(q13;q34)
was seen in cases 13 and 14, which were bilateral
tumors from the same woman. In case 1, three unre-
lated clones with a single numerical aberration in each
were identified. In case 16, three related clones were
seen: 49, XX, +3, +7, i(8)(q10), +12[15]/50, idem, +r[2]/
50, idem, -r, +mar[2]. Numerical changes only were
Table 1: Borderline Ovarian Tumors Examined by Karyotyping, High Resolution-CGH, and Microsatellite Instability
Analysis. (Continued)
19/04-831 A serous
(left ovary)
yes invasive
implants
46, XX[84] rev ish enh(2q24, 3p12, 3p13, 8q22q23, 13q22q31), dim
(2q36q37, 7q35q36, 9q33q34, 10q25q26, 11q13,
12q23q24, 14q31q32, 15q22q24, 16p11p13, 17p11p13,
17q11q21, 17q22q25, 19p13, 19q13, 20q11q13, 22q)
MSS
20/04-832 B serous
(right
ovary)
yes invasive
implants
47, XX, +7[18] rev ish enh(Xq21q23, 2q22q32, 3p12p13, 3q12q13,
4q12q28, 5p13p14, 5q14q23, 6q12q21, 6q22, 7p12p21,
7q21q34, 8q13q21, 8q22q23, 9p21p24, 11q14q21,
13q21q31), dim(1p32pter, 2q37, 4p16, 6p23, 6q25q26,
9q34, 10q25q26, 11q12q13, 12q23q24, 14q31q32,
15q22q24, 16p11p13, 16q21q24, 17p, 17q11q21,
17q23q24, 19, 20q11q13, 21q22, 22q)
MSS
21/04-1211 mucinous no no Culture failure no imbalances MSS
22/04-1213 A serous
(right
ovary)
yes invasive
implants
46, XX[3] rev ish enh(8p11p23, 8q11q24), dim(1p34p35, 15q11q13,
16p11p12)
MSS
23/04-1214 B serous
(left ovary)
yes invasive
implants
46, XX[3] no DNA available –
Figure 1 Histological sections from case 17 (a) a mucinous and case 7 (b), a serous borderline ovarian tumor.
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Page 4 of 9found in three cases. Chromosomes 7 and 12 were most
often involved in numerical changes (in three cases
each, always as trisomies), whereas chromosomal band
3q13 was involved in the three cases showing only a
structural rearrangement.
The HR-CGH gave informative results in 19 samples
showing genomic imbalances in 11 of them (Table 1).
From four lesions there was no DNA available for analy-
sis. In six cases, the G-banding karyotype matched the
pattern detected by CGH; five of them had a normal
karyotype and showed no imbalances by HR-CGH
whereas the last tumor (case 16) had numerical and
structural changes all detected by both techniques. In
six tumors, HR-CGH detected imbalances where G-
banding analysis showed only normal karyotypes.
The tumors showed from five (samples 16 and 22) to
41 (sample 1) imbalances by HR-CGH with an average
number of copy alterations (ANCA) index of 18.72. No
amplifications were scored. The major copy number
changes detected in the borderline tumors were gains
from chromosome arms 2q, 6q, 8q, 9p, and 13q and
losses from 1p, 12q, 14q, 15q, 16p, 17p, 17q, 19p, 19q,
and 22q (Fig. 2). More specifically, the most frequently
gained bands were, in order of decreasing frequency,
8q23 (82% of the cases showing imbalances), and 2q24,
6q15~16, 8q13~21, 9p23, and 13q22~31 (36%). The
most frequently lost bands were 1p34~35, 17p12~13,
19p13, 19q13, and 22q11~12 (73%), 17q12~21 (64%),
16p11~13 (55%), 15q22~24, and 17q23~24 (45%), and
12q23~24 and 14q31 (36%).
The HR-CGH analysis gave informative results from
both tumorous ovaries in two patients with bilateral dis-
ease (cases 13 and 14 and 19 and 20). The common
imbalances found in these samples were gains of 2q24,
8q22~23, and 13q22~31 and losses of 9q34, 10q25~26,
12q23~24, 14q31~32, 15q22~24, 16p, 17p, 17q11~21,
17q23~24, 20q and 22q.
FISH was performed for two purposes: to characterize,
possibly identify, the common breakpoint in 3q13 (seen
in cases 3, 13, and 14; the latter two were from bilateral
tumors in the same woman) and to test for the consis-
tent deletion previously found in borderline ovarian
Figure 2 The genomic imbalances detected by HR-CGH in 11 borderline ovarian tumors. Gains are shown in green and losses in red
color.
Table 2 Clones Used for FISH Experiments.
BAC clone Map position UCSC position (hg18)
RP11-631J1 3q12.2 chr3:101, 560, 061-101, 723, 941
CTD-2303M9 3q13.2 chr3:113, 489, 978-113, 592, 063
RP11-514O12 6q27 chr6:167, 113, 548-167, 270, 484
CTD-2383F8 6q27 chr6:167, 253, 486-167, 374, 339
CTD-3184N3 6q27 chr6:167, 404, 540-167, 588, 046
RP11-931J21 6q27 chr6:167, 592, 153-167, 765, 915
RP11-178P20 6q27 chr6:167, 616, 370-167, 765, 926
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FISH was performed on cases 13 and 14 on previously
hybridized (stripped) slides; however, we did not get
informative results. To examine for 6q deletions, FISH
was performed on a total of 12 tumors. In nine cases,
newly dropped slides were made, whereas in three cases
old slides previously used for other FISH experiments
were stripped and used. Because no metaphase spreads
were available for FISH analysis, interphase nuclei were
used to check for the reported deletion on 6q. A total of
200 nuclei per sample were analyzed but no indication
of a deletion of the alleged 6q target region was detected
in the nine cases yielding informative results.
The testing for MSI gave informative results in 18
tumors. All of them were classified as microsatellite
stable (MSS) as none of the tumor genotypes showed an
aberrant pattern. The remaining five samples were not
analyzed because there was no DNA available.
Discussion
FISH experiments were performed to investigate
whether the about 300 kb deletion in 6q27 found so
consistently by Tibiletti et al. [2] in borderline ovarian
tumors was a feature also of the tumors of our series. In
none of nine informative cases (five with a normal kar-
yotype, four with clonal chromosome abnormalities) did
we see any such deletion. We cannot offer any biological
explanation for the discrepant results, and so future stu-
dies will be necessary to find out what is more typical of
borderline tumors.
MS status has previously been analyzed in a total of
112 ovarian tumors of borderline malignancy, 14 of
which showed instability for one or more of the markers
used. However, some studies were performed before the
consensus reached by NCI for evaluating MSI [29] and
therefore differences in the type and number of micro-
satellites can be found in these studies [31-36]. All 18
informative borderline ovarian tumors examined by us
turned out to be microsatellite stable (MSS). Based on
the results of our and the latest other studies [34-36], it
therefore seems that at least the great majority of ovar-
ian tumors of borderline malignancy tend to have a
stable MS pattern.
The pattern of chromosomal aberrations seen by G-
banding analysis in the present study with gains of chro-
mosomes 7 and 12 as recurrent changes is largely simi-
lar to that previously found in abnormal karyotypes of
ovarian borderline tumors and well differentiated carci-
nomas [8,9]. Poorly differentiated and/or advanced stage
ovarian carcinomas, on the other hand, tend to have
more complex karyotypes with multiple numerical as
well as structural aberrations [18,37]. A novel finding,
however, was that three tumors (cases 3, 13, and 14;
admittedly, the last two were from the same patient)
showed a single structural aberration that seemed to
involve chromosomal band 3q13. Unfortunately, we did
not have left fixed cells in suspension to perform FISH
experiments on newly dropped slides, and our attempts
to use stripped slides for better FISH characterization
failed. Nevertheless, the detected G-banding similarity
hints that one or more genes mapping to this band may
play a pathogenetic role in a subset of borderline ovar-
ian tumors.
Most tumor karyotypes in the present series were nor-
mal, as only seven of 21 successfully cultured samples
showed clonal chromosome abnormalities. The simplest
explanation for this is that the cells carrying aberrations
did not divide in vitro and therefore could not be
detected by G-banding analysis. Confirmation that this
was indeed so stems from the observation that six
tumors with a normal karyotype showed genomic imbal-
ances by HR-CGH. However, in the five tumors where
both G-banding and HR-CGH analyses gave a normal
karyotype and no imbalances, one must assume that
either no aberrations were present in at least a substan-
tial minority of the cells or they were too small to be
seen at the chromosomal resolution level.
The major copy number changes detected in the bor-
d e r l i n et u m o r sw e r eg a i n so fc h r o m o s o m a lb a n d so r
regions 8q23 (present in 82% of the cases showing
imbalances), 2q24, 6q15~16, 8q13~21, 9p23, and
13q22~31 (36%), and losses of 1p34~35, 17p12~13,
19p13, 19q13, 22q11~12 (73%), 17q12~21 (64%),
16p11~13 (55%), 15q22~24, and 17q23~q24 (45%), and
12q23~24 and 14q31 (36%). Some of these imbalances
have already been reported by other groups such as gain
of 8q and losses of 1p and chromosome 17
[12,14-16,38]. However, the use of HR-CGH allowed us
to increase the resolution and narrow down the men-
tioned regions to 8q23, 1p34~35, 17p12~13, 17q12~21,
and 17q23~24. Additional studies are needed to better
investigate the nature of the gene(s) present here that
may be involved in the genesis or progression of ovarian
borderline tumors.
Much interest has focused on the loss of genetic infor-
mation from chromosome 17 in ovarian tumors. In the
short arm, losses seem to occur especially at 17p13.3
[39-41] with OVCA1 and OVCA2 as possible target
tumor suppressor genes [42]. However, proximal 17p
changes have received more attention. Mutation of the
gene TP53 in 17p13.1 is the most common genetic
alteration thus far detected in ovarian cancer, with
mutation rates as high as 50% in advanced stage carci-
nomas [43]. The frequency of TP53 alterations varies
depending on whether the tumors are benign, border-
line, or malignant as well as on the histological subtype,
i.e., serous, mucinous, endometrioid, and clear cell ovar-
ian carcinoma. In benign epithelial ovarian tumors no
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line tumors, TP53 mutation and over-expression may
occur, but are not common [46-48]. In malignant
tumors, the prevalence of TP53 gene mutations
increases with increasing stage [44]. In the long arm of
chromosome 17, losses at 17q12~21 are frequently
observed in ovarian carcinomas [39,49], but this is the
first time that chromosomal regions 17q12~21 and
17q23~24 are identified as lost in ovarian borderline
tumors. The breast and ovarian cancer susceptibility
gene BRCA1 maps to 17q21 and could be one possible
gene target, but the actual pathogenetic involvement of
this and other genes located in 17q needs to be further
investigated.
The present series of borderline ovarian tumors is the
largest one hitherto analyzed for genomic imbalances
a n dt h ef i r s te x a m i n e db yH R - C G H .I na d d i t i o nt ot h e
above-mentioned imbalances, we also identified some
new chromosomal regions gained at a high frequencies,
i.e., 2q24, 6q15~16, 8q13~21, 9p23, and 13q22~31
(36%), as well as losses of 19p13, 19q13, and 22q11~12
(73%), 16p11~13 (55%), 15q22~24 (45%), and 12q23~24
and 14q31 (36%). Again, further studies are needed to
investigate the possible involvement of genes present
here in ovarian tumorigenesis. The aberrations found in
the two histological subtypes of borderline tumors (ser-
ous versus mucinous) were also compared but no speci-
fic difference was noted.
The present series included five patients with bilateral
borderline tumors. Informative results were obtained by
HR-CGH from both tumorous ovaries in two patients
(pairs 13 and 14 and 19 and 20). Cases 13 and 14
showed the same unbalanced 3;4-translocation by karyo-
typing in both tumorous ovaries. This is a sure sign that
the bilateral tumors were part of a single neoplastic pro-
cess and, hence, that one of them must have occurred
by a metastatic mechanism. No imbalances were seen by
HR-CGH in this tumor pair, probably because too little
was contributed by cells of the neoplastic parenchyma
to the total DNA extracted. In cases 19 and 20, a +7
was seen in one tumor whereas the other showed a nor-
mal karyotype; this technique therefore did not yield
certain information as to the two tumors’ clonal rela-
tionship. However, common imbalances were found by
HR-CGH such as gains of 2q24, 8q22~23, and
13q22~31 and losses of 9q34, 10q25~26, 12q23~24,
14q31~32, 15q22~24, 16p, 17p, 17q11~21, 17q23~24,
20q and 22q. The data are too small for anything but
speculations, but it is possible that these bands/regions
may carry gene(s) important for the development of
bilateral borderline ovarian tumors. It is in this context
intriguing that the same imbalances also occurred in
some of the other bilateral tumors, albeit then found in
only one tumorous ovary while the other was uninfor-
mative. But regardless of what, if any, pathogenetic
changes might contribute to the development of bilat-
eral borderline tumors particularly, the combined karyo-
typic/CGH data on the two only completely informative
pairs strongly indicate that bilaterality occurs by spread-
ing from one side to the other, not as two clonally sepa-
rate processes.
The average number of copy alterations per tumor
calculated in the present series was 18.72. It is interest-
ing to note that for the bilateral borderline ovarian
tumors the ANCA index was 24.5 whereas for the uni-
lateral borderline ovarian tumors it was 17.44. This dif-
ference, small though it may seem, is consistent with
the interpretation that bilateral tumors reflect a more
advanced disease stage compared with unilateral ones,
inasmuch as they arise via the spreading process
referred to above.
Conclusion
T h ei n t r o d u c t o r yq u e s t i o na st ow h e t h e rb o r d e r l i n e
tumors of the ovary represent a transitional stage from
benign to clearly malignant or a pathogenetically
“closed” tumor type of its own, without a tendency to
further progression, remains, perhaps not surprisingly,
unanswered by the findings of the present study. It may
be worthy of note, however, that two main genomic
groups of tumors were discerned in this series, one (n =
5) showing a normal karyotype and no imbalances
detectable by HR-CGH and the other (n = 14) showing
aberrations by one or both analytical methods. Possibly,
and we underscore that this is presently only a specula-
tion, tumors of the first group are more developmentally
stable and may have no propensity to progress to more
malignant carcinomas, whereas those of the second
group with chromosomal/genomic aberrations may
undergo further evolutionary changes giving rise to a
more malignant phenotype. The fact that gain of chro-
mosomal band 8q23, as well as losses of 19p13 and
19q13, feature prominently in both overt carcinomas
[37,50] and in the present series (the gains were found
in 5 of 5 cases with bilateral borderline tumors and in 4
of 6 informative unilateral tumors showing imbalances)
fits, but by no means proves, this hypothesis. To further
validate it would require more extensive studies that
should not only compare the karyotypic/genomic find-
ings of borderline and malignant tumors, but should
also collate these findings with clinical information on
the same group of patients.
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